|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Sixteen HLA-B alleles groups were associated with HIV-1 infection; seven of them (43.8%) were related to slow disease progression or reduced risk of MTCT, while six (37.5%) alleles groups were linked to a faster progression of HIV infection in children and to increased risk of MTCT.
|
30772367 |
2019 |
|
HIV Infections
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In early HIV infection, host expression of the protective HLA-B*81 allele was associated with lower RC (<i>P</i> = 0.05), as was expression of HLA-B*07 (<i>P</i> = 0.02), suggesting early immune-driven attenuation of RT-integrase by these alleles.
|
29997209 |
2018 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In combination with the protective Gag KK10 and Pol KY9 CD8<sup>+</sup> T-cell responses that dominate HIV-specific CD8<sup>+</sup> T-cell activity in HLA-B*27:05-positive subjects, a Nef VW9-specific response is additionally present and immunodominant in HLA-B*27:02-positive subjects, mediated through a polymorphism at residue 81 in the F pocket, that contributes to selection pressure against HIV.<b>IMPORTANCE</b> CD8<sup>+</sup> T cells play a central role in successful control of HIV infection and have the potential also to mediate the eradication of viral reservoirs of infection.
|
29167337 |
2018 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The factors determining differential HIV disease outcome among individuals expressing protective HLA alleles such as HLA-B*27:05 and HLA-B*57:01 remain unknown.
|
29338738 |
2018 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
HLA-B*14:02-Restricted Env-Specific CD8<sup>+</sup> T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.
|
28878089 |
2017 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Carriage of alleles encoding certain inhibitory natural killer (NK) cell receptor/HLA ligand KIR3DL1/HLA-B combinations is associated with protection from HIV infection and slow time to AIDS, implicating NK cells in HIV control.
|
27499379 |
2017 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.
|
28369189 |
2017 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
|
28062682 |
2017 |
|
HIV Infections
|
0.500 |
AlteredExpression
|
group |
BEFREE |
A similar scenario is observed in humans where the expression of HLA-B*27 or HLA-B*57 has been linked to slow or no progression to AIDS after HIV infection.
|
26811146 |
2016 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Rapid human immunodeficiency virus disease progression is associated with human leukocyte antigen-B homozygocity and human leukocyte antigen-B51 in a cohort from Manitoba, Canada.
|
25746818 |
2015 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Kaplan Meier analysis revealed significantly increased mortality in HLA-B*57-positive patients with HIV-infection (p=0.032) and HIV/HCV-co-infection (p=0.004), which was apparently linked to non-viral infections.
|
26241854 |
2015 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
HLA-B*57 is the HLA class I molecule that affords the greatest protection against disease progression in HIV infection.
|
24501417 |
2014 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The HLA-B*57 allele, which is associated with a better clinical outcome in HIV infection, is overrepresented in HIC.
|
24131719 |
2014 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
As B35 is the most prevalent HLA-B in Mexico, we investigated HIV disease outcome in relation to HLA expression in a large cohort (n=976) of Mexicans.
|
24853499 |
2014 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These data corroborate the existence of significant differences in HLA-B allele frequencies among the distinct AIDS progression profiles and further elucidate the role of HLA alleles in the outcome of HIV infections in diverse populations.
|
24718028 |
2014 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In Zambia, ReA is associated with the HLA-B*57:03 allele, which is paradoxically also associated with slow progression of HIV infection.
|
24744085 |
2014 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
HIV subtype influences HLA-B*07:02-associated HIV disease outcome.
|
24010680 |
2014 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Hence, aim of this study was to document association of HLA-B with HIV infection in DCs living in Mumbai, India.
|
24029662 |
2014 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
HLA-B*57 alleles and the closely related HLA-B*5801 are often grouped together because of their similar peptide-binding motifs and HIV disease outcome associations.
|
22090105 |
2012 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
The difference between these frequencies is probably due to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral therapy and B*5701 typing.
|
21221482 |
2011 |
|
HIV Infections
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In addition, these studies identify a factor contributing to different HIV disease outcomes in individuals expressing HLA-B*5703.
|
21498667 |
2011 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
An alternative possibility is that a small number of HLA-B alleles may have a very strong impact on HIV disease outcome, dominating the contribution of other HLA alleles.
|
20660184 |
2010 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These data are consistent with others that associated protection from HIV disease with inherent host HLA B allele-mediated ability to induce broader Gag T-cell targeting coupled with apparent virological control.
|
19142234 |
2009 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
In two HIV C clade-infected populations in South Africa and Zambia, we sought to elucidate the role of HLA-B*5703 in HIV disease outcome.
|
19307327 |
2009 |
|
HIV Infections
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection.
|
18614872 |
2008 |